Release issued 8th February 2002

Istanbul, Turkey - Embil Pharmaceutical Co. Ltd. announced today, the rapid In-vitro percutanous penetration profile data validating the unique properties of its patented Lamellar Promoting System (LPS) used in the topical delivery of Nimesulide, has been accepted for presentation at the upcoming 8'th International Conference on Percutaneous Penetration (www.pppconference.org) due to take place in Antibes Juan-Les Pins, France between the dates of 2-6 April 2002.This unique LPS system developed by Embil has shown that it can significantly enhance the percutaneous absorption of topical active compounds. In this particular case the enhanced penetration of Nimesulide should result "a priori" in superior product efficacy.

(17th November 2004) Sulidin® 1% Nimesulide LPS® gel receives European and US Patents

(7th November 2004) New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004.

(29th December 2003) Two papers on Neo-Penotran® Forte and Neo-Penotran® Forte-L have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004

(6th June 2003) Australian Patent Approval announced for SULIDIN LPS (Topical Nimesulide Gel) formulation.

(10th October 2002) Recent Patent Approvals for SULIDIN® LPS® (Topical Nimesulide Gel)